Cargando…
KDM6A promotes imatinib resistance through YY1-mediated transcriptional upregulation of TRKA independently of its demethylase activity in chronic myelogenous leukemia
Rationale: Despite landmark therapy of chronic myelogenous leukemia (CML) with tyrosine kinase inhibitors (TKIs), drug resistance remains problematic. Cancer pathogenesis involves epigenetic dysregulation and in particular, histone lysine demethylases (KDMs) have been implicated in TKI resistance. W...
Autores principales: | Zhang, Chengwan, Shen, Li, Zhu, Yifu, Xu, Ran, Deng, Zhikui, Liu, Xiaoning, Ding, Yihan, Wang, Chunling, Shi, Yuye, Bei, Liye, Wei, Dongping, Thorne, Rick F., Zhang, Xu Dong, Yu, Liang, Chen, Song |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7806474/ https://www.ncbi.nlm.nih.gov/pubmed/33456567 http://dx.doi.org/10.7150/thno.50571 |
Ejemplares similares
-
Homoharringtonine enhances the effect of imatinib on chronic myelogenous leukemia cells by downregulating ZFX
por: Wu, Jingjing, et al.
Publicado: (2019) -
KDM6 Demethylases and Their Roles in Human Cancers
por: Hua, Chunyan, et al.
Publicado: (2021) -
Functions and Interactions of Mammalian KDM5 Demethylases
por: Pavlenko, Egor, et al.
Publicado: (2022) -
The treatment of pediatric chronic myelogenous leukemia in the imatinib era
por: Lee, Jae Wook, et al.
Publicado: (2011) -
KDM6A/B Demethylases in Gut Homeostasis
por: Soshnikova, Natalia
Publicado: (2023)